Cited by 448Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Open access

Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose·2014·Journal of Thoracic Oncology

DOI 10.1097/jto.0000000000000263PMC PMC4224589

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS: Mandatory tumor and duplicate plasma (1 and 2) baseline samples were collected (all screened patients; n = 1060). Preplanned, exploratory analyses included EGFR mutation (and subtype) status of tumor versus plasma and between plasma samples. Post hoc, exploratory analyses included efficacy by tumor and plasma EGFR mutation (and subtype) status. RESULTS: Available baseline tumor samples were 1033 of 1060 (118 positive of 859 mutation status known; mutation frequency, 13.7%). Available plasma 1 samples were 803 of 1060 (82 positive of 784 mutation status known; mutation frequency, 10.5%). Mutation status concordance between 652 matched tumor and plasma 1 samples was 94.3% (95% confidence interval [CI], 92.3-96.0) (comparable for mutation subtypes); test sensitivity was 65.7% (95% CI, 55.8-74.7); and test specificity was 99.8% (95% CI, 99.0-100.0). Twelve patients of unknown tumor mutation status were subsequently identified as plasma mutation-positive. Available plasma 2 samples were 803 of 1060 (65 positive of 224 mutation status-evaluable and -known). Mutation status concordance between 224 matched duplicate plasma 1 and 2 samples was 96.9% (95% CI, 93.7-98.7). Objective response rates are as follows: mutation-positive tumor, 70% (95% CI, 60.5-77.7); mutation-positive tumor and plasma 1, 76.9% (95% CI, 65.4-85.5); and mutation-positive tumor and mutation-negative plasma 1, 59.5% (95% CI, 43.5-73.7). Median progression-free survival (months) was 9.7 (95% CI, 8.5-11.0; 61 events) for mutation-positive tumor and 10.2 (95% CI, 8.5-12.5; 36 events) for mutation-positive tumor and plasma 1. CONCLUSION: The high concordance, specificity, and sensitivity demonstrate that EGFR mutation status can be accurately assessed using circulating-free tumor DNA. Although encouraging and suggesting that plasma is a suitable substitute for mutation analysis, tumor tissue should remain the preferred sample type when available.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000263

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241
Self-citation
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786

Show all 28 references

Research works printed but not linked: 2

Reck, 2013, Investigating the utility of plasma-derived circulating-free DNA for the detection of EGFR mutations in European and Japanese patients with advanced NSCLC: ASSESS study design, J Thorac Oncol, S483
Han, 2013, A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with NSCLC of adenocarcinoma and non-adenocarcinoma histology: IGNITE study design, J Thorac Oncol, 8, S1098

Sorted by citations

Items 301–400 of 448

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
Fujii, H., Nagakura, H., Kobayashi, N., Kubo, S., Tanaka, K., Watanabe, K., Horita, N., Hara, Y., Nishikawa, M., Miura, K., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10135-z · Cited by 12
Molecular pathology in real time
Ryška, A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9607-3 · Cited by 12
Microfluidics for minute DNA sample analysis: open challenges for genetic testing of cell-free circulating DNA in blood plasma
Malbec, R., Cacheux, J., Cordelier, P., Leïchlé, T., Joseph, P., & Bancaud, A. (2018) · Micro and Nano Engineering · doi:10.1016/j.mne.2018.10.003 · Cited by 12
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
Verzè, M., Minari, R., Gnetti, L., Bordi, P., Leonetti, A., Cosenza, A., Ferri, L., Majori, M., Filippo, M. D., Buti, S., et al. (2021) · Cancers · doi:10.3390/cancers13215403 · Cited by 12
Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples
Chougule, A., & Basak, S. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_540_17 · Cited by 11
Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome
Moiseenko, F. V., Волков, Н. М., Жабина, А. С., Stepanova, M., Rysev, N., Klimenko, V. V., Myslik, A. V., Artemieva, E. V., Egorenkov, V. V., Abduloeva, N. K., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100524 · Cited by 11
Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance
Nishikawa, S., Kimura, H., Koba, H., Yoneda, T., Watanabe, S., Sakai, T., Hara, J., Sone, T., Kasahara, K., & Nakao, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.144 · Cited by 10
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Tissot, C., Gay, P., Brun, C., & Froudarakis, Μ. E. (2019) · The Clinical Respiratory Journal · doi:10.1111/crj.13005 · Cited by 11
Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer
Zhang, X., Li, C., Ye, M., Hu, Q., Hu, J., Gong, Z., Li, J., Zhao, X., Xu, Y., Zhang, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602402 · Cited by 10
Place du NGS (Next Generation Sequencing) et de l’ADN tumoral circulant dans le testing moléculaire des cancers bronchiques
Pécuchet, N., Legras, A., Laurent‐Puig, P., & Blons, H. (2016) · Annales de Pathologie · doi:10.1016/j.annpat.2015.11.012 · Cited by 10
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia
Loong, H. H.-F., Raymond, V. M., Shiotsu, Y., Chua, D. T. T., Teo, P. M. L., Yung, T., Skrzypczak, S. M., Lanman, R. B., & Mok, T. S. K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.022 · Cited by 10
EGFR Mutation Analysis in Non-small Cell Lung Carcinoma Patients: A Liquid Biopsy Approach
Joshi, J. S., Raval, A. P., Desai, U., Upadhyay, V., Bhavsar, M., Shah, K., Rawal, R., Panchal, H. P., & Shah, F. D. (2019) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-019-00864-7 · Cited by 10
Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
Tran, V. T., Phan, T. T., Nguyen, S. T., Tran, B., Ho, T. T., Pho, S. P., Nguyen, T. B., Pham, T. T. B., Le, A. T., Le-Thuong, V., et al. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05209-9 · Cited by 11
Construction of a reference material panel for detecting KRAS / NRAS / EGFR / BRAF / MET mutations in plasma ctDNA
Xu, J., Qu, S., Sun, N., Zhang, W., Zhang, J., Song, Q., Lin, M., Gao, W., Zheng, Q., Han, M., et al. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206745 · Cited by 10
A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
Jensen, S. G., Epistolio, S., Madsen, C. L., Kyneb, M. H., Riva, A., Paganotti, A., Barizzi, J., Petersen, R. K., Børgesen, M., Molinari, F., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253687 · Cited by 10
Nucleic acid-based reference materials: A “ruler” for precision molecular diagnostics
Li, K., Guo, Y., Qi, X., Li, F., Li, F., Yang, M., Zhou, J., Zhou, H., Liu, G., & Li, L. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118268 · Cited by 9
EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
Pender, A., Hughesman, C. B., Law, E., Kristanti, A., McNeil, K., Wong, S. K., Tucker, T., Bosdet, I., Young, S. S., Laskin, J. J., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-581 · Cited by 9
Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
Prabhash, K., Parikh, P. M., Rajappa, S. J., Noronha, V., Joshi, A., Aggarwal, S., Bondarde, S. A., Patil, S. G., Desai, C. J., Dattatreya, P. S., et al. (2018) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_30_18 · Cited by 9
Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
Hung, M., Lung, J., Lin, Y., Fang, Y., Huang, S., Jiang, Y., Hsieh, M., & Tsai, Y. (2019) · Cancers · doi:10.3390/cancers11060803 · Cited by 9
Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
Morán, T., Felip, E., Bosch‐Barrera, J., de Aguirre, I., Ramírez, J. L., Mesía, C., Carcereny, E., Roa, D., Sais, È., García, Y. G., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25478 · Cited by 9
Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer
Lazzari, C., Gregorc, V., Cangi, M. G., Giovannetti, E., Bulotta, A., & Santarpía, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.17 · Cited by 9
Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study
Mangum, R., Reuther, J., Sen Baksi, K., Gandhi, I., Zabriskie, R. C., Recinos, A., Raesz-Martinez, R., Lin, F. Y., Potter, S. L., Sher, A. C., et al. (2023) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2023.2228837 · Cited by 8
Liquid biopsy - emergence of a new era in personalized cancer care
Abraham, J., Singh, S., & Joshi, S. P. (2018) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-018-0053-0 · Cited by 8
Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA
Kessler, M. D., Pawar, N. R., Martin, S. S., Antalis, T., & O’Connor, T. D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.004 · Cited by 9
Recent advances in lung cancer genomics: Application in targeted therapy
Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 9
Tissue Versus Liquid Biopsy: Opposite or Complementary?
Arancio, W., Belmonte, B., Castiglia, M., Napoli, A. D., & Tripodo, C. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_4 · Cited by 8
The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer
Suryavanshi, M., Mehta, A., Panigrahi, M. K., Jaipuria, J., Saifi, M., Jain, K., Kumar, D., Verma, H., Sharma, S. K., Batra, U., et al. (2018) · Lung India · doi:10.4103/lungindia.lungindia_472_17 · Cited by 8
EGFR T790M detection in formalin‐fixed paraffin‐embedded tissues of patients with lung cancer using RNA‐based in situ hybridization: A preliminary feasibility study
Wu, S., Shi, X., Si, X., Liu, Y., Lu, T., Zhang, L., Liang, Z., & Zeng, X. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13169 · Cited by 7
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
Jian, H., Li, W., Ma, Z., Huang, J., Feng, J., Song, Y., Gao, B., Zhu, H., Tao, M., Bai, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08399-8 · Cited by 9
Quel avenir pour l’ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques
Pietrasz, D., Pécuchet, N., Fabre, E., Blons, H., Chevalier, L., Taly, V., Laurent‐Puig, P., & Bachet, J. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.10.017 · Cited by 7
Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma
Łochowska, B., Nowak, D., & Białasiewicz, P. (2019) · Advances in respiratory medicine · doi:10.5603/arm.2019.0019 · Cited by 7
Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice
Park, S., Lee, J.-C., & Choi, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112236 · Cited by 7
Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
Li, S., Wu, M., Wang, H., Hsu, P., Fang, Y., Wang, C.-L., Chu, H.-C., Lin, H.-C., Lee, L., Wu, C.-Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810661 · Cited by 7
Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey
Büyükşimşek, M., TOĞUN, M., Oguz, K. I., Bişgin, A., Boğa, İ., Tohumcuoğlu, M., Oğul, A., Yetişir, A. E., Şahin, B., Sümbül, H. E., et al. (2019) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2019-0016 · Cited by 7
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assayPreprint
Brannon, A. R., Jayakumaran, G., Diosdado, M. S., Patel, J., Razumova, A., Hu, Y., Meng, F., Haque, M., Sadowska, J., Murphy, B. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.27.175471 · Cited by 7
‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma
Rathor, A., Malik, P. S., Tanwar, P., Khurana, S., Baskarane, H., Pushpam, D., Nambirajan, A., & Jain, D. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05828-w · Cited by 6
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience
Jha, P., Mishra, R., Joshi, A., Sharma, N., Shah, M. J., Babu, G., Rauthan, A., Limaye, S. A., Menon, N. S., Ramachandran, V., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100300 · Cited by 6
Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
Barr, M. P., Baird, A., Halliday, S. R., Martin, P., Allott, E. H., Phelan, J. J., Korpanty, G., Coate, L. E., O’Brien, C. P., Gray, S. G., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102360 · Cited by 6
The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
Zhang, S., Yang, L., Yang, Y., Yang, G., Xu, H., Niu, X., & Wang, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6545 · Cited by 6
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Osei, E. K., Lumini, J., Gunasekara, D., Osei, B., Asare, A. G., & Laflamme, R. (2019) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396919000876 · Cited by 6
Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma
Son, S.-M., Woo, C. G., Han, H. S., Lee, K. H., Lim, Y. H., & Lee, O.-J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1139 · Cited by 6
Evaluation of PCR‐HRM, RFLP, and direct sequencing as simple and cost‐effective methods to detect common EGFR mutations in plasma cell–free DNA of non–small cell lung cancer patients
Zaini, J., Syahruddin, E., Yunus, M., Andarini, S., Hudoyo, A., Masykura, N., Yasril, R., Ridwanuloh, A. M., Hidajat, H., Nurwidya, F., et al. (2019) · Cancer Reports · doi:10.1002/cnr2.1159 · Cited by 6
Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment
Bianchi, F. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.598 · Cited by 5
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Remón, J., Gorham, J., Besse, B., & Sculier, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.01482-2015 · Cited by 5
Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations.
Milano, G. A. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.12.04 · Cited by 5
„Liquid biopsy“: Analyse molekularer Marker aus Blutproben zur Therapiesteuerung beim Lungenkarzinom
Brueckl, W. M., Wirtz, R. M., Bertsch, T., Ficker, J. H., & Jung, A. (2017) · Pneumologie · doi:10.1055/s-0042-123803 · Cited by 5
Identification of circulating tumor DNA using a targeted 545‑gene next generation sequencing panel in patients with gastric cancer
Lan, J., Lu, Y., Guan, Y., Chang, L., Yu, Z., & Qian, H. (2020) · Oncology Letters · doi:10.3892/ol.2020.11305 · Cited by 5
Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center
Assi, H. I., Tfayli, A., Assaf, N., Daya, S. A., Bidikian, A., Kawsarani, D., Fermanian, P., Zaatari, G. S., & Mahfouz, R. A. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04797-5 · Cited by 5
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
Chen, Z., Shen, S., Shi, W., Jiang, G., Wang, X., Jian, H., Zhou, Z., Ding, Z., & Lü, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189287 · Cited by 5
Circulating tumor DNA detection in hepatocellular carcinoma
Cabel, L., Proudhon, C., Buecher, B., Pierga, J., & Bidard, F. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy111 · Cited by 5
Using CTCs for pharmacogenomic analysis
Hart, C. D., Galardi, F., Pestrin, M., Luca, F. D., Risi, E., & Leo, A. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.019 · Cited by 4
Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer
Mirtavoos‐Mahyari, H., Ghadami, M., Khosravi, A., Esfahani‐Monfared, Z., Seifi, S., Motevaseli, E., Toutkaboni, M. P., & Modarressi, M. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.12.3591 · Cited by 3
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study
Randrian, V., Adenis, A., Desrame, J., Barbier, E., Fiore, F. D., Lièvre, A., Dahan, L., Laurent‐Puig, P., Mineur, L., Breysacher, G., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.11.014 · Cited by 4
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
Janke, F., Bozorgmehr, F., Wrenger, S., Dietz, S., Heußel, C. P., Heußel, G., Silva, C. F., Rheinheimer, S., Feißt, M., Thomas, M., et al. (2020) · Cancers · doi:10.3390/cancers12040954 · Cited by 4
Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report
Wang, Y., Gao, Y., Chen, H., Liu, H., Fu, X., Yan, R., You, F., & Li, Z.-H. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211028571 · Cited by 4
ADN tumoral circulant : principes, applications actuelles en radiothérapie et développement futur
Castelli, J., Cabel, L., Bidard, F., Duvergé, L., & Bachet, J. (2018) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2018.06.018 · Cited by 4
State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA
Heliebi, A. E., & Heitzer, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00005-8 · Cited by 4
CTCs as Liquid Biopsy: Where Are We Now?
Cayrefourcq, L., & Alix‐Panabières, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84366 · Cited by 4
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA : Liquid‐Lung‐A
Park, C., Lee, S. Y., Lee, J. C., Choi, C., Lee, S. Y., Jang, T. W., Oh, I., & Kim, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13763 · Cited by 4
Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification
Surani, A. A. (2016) · British Journal of Pharmacy · doi:10.5920/bjpharm.2016.07 · Cited by 3
Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis
Mao, X., Zhang, Y., Xie, F., Zheng, X., & Sun, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20291 · Cited by 3
Circulating tumor DNA analysis in patients with EGFR mutant lung cancer
Nanjo, S., & Bivona, T. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.106 · Cited by 3
A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
Zhang, Y., Ye, L., Zhang, H., Chen, X., Ji, H., Chen, G., Zhang, L., Zhang, T., & Jin, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.101 · Cited by 3
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
Pan, G., Chen, K., Yu, X., Sheng, J., & Fan, Y. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-223 · Cited by 3
Comparison of EGFR mutations detected by LNA-ARMS PCR in plasma ctDNA samples and matched tissue sample in non-small cell lung cancer patients.
Jin, J., He, J., Yan, X., Zhao, Y., Zhang, H., Zhuang, K., Wen, Y., & Gao, J. (2022) · PubMed Central · Cited by 3
Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer
Rossi, G., Bargellini, I., Bonifazi, M., Camplese, P., Candoli, P., Ceron, L., Gasparini, S., Granone, P. L., Grossi, F., Iezzi, R., et al. (2019) · EMJ Oncology · doi:10.33590/emjoncol/10311320 · Cited by 3
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Osimertinib (Tagrisso®) : activité, indication et modalités d’utilisation dans les cancers bronchiques non à petites cellules
Leprieur, E. G., Cortot, A. B., Cadranel, J. L., & Wislez, M. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.06.007 · Cited by 3
Detection and characterization of circulating cell free tumor DNA in cancer patients with malignant solid tumors. Liquid biopsy: a new tool in molecular pathology?
Hinrichsen, T., Dworniczak, J. K., Wachter, O., Dworniczak, B., & Dockhorn‐Dworniczak, B. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0035 · Cited by 3
Les avancées dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le réanimateur
Pinsolle, J., Terzi, N., Ferrer, L., Levra, M. G., Toffart, A., & Moro‐Sibilot, D. (2019) · Médecine Intensive Réanimation · doi:10.3166/rea-2019-0091 · Cited by 4
Osimertinib (TAGRISSO™) and the cobas® EGFR Mutation Test v2
Jenkins, S. C., Cross, D. A. E., & Scudder, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813539-6.00023-7 · Cited by 3
Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
Yuan, C., Jiang, H., Jiang, W., Wang, H., Su, C., & Zhou, S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s329900 · Cited by 3
Personalized Medicine in Oncology
Vanderwalde, A. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2820-5 · Cited by 4
Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy
Yan, K., Bakhtiah, A., Hota, S., Evans, J. S., & Mo, F. K. F. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01173-1 · Cited by 2
The Use of Circulating Biomarkers in Early Clinical Trials in Patients With Cancer
D’Arcangelo, M., Margetts, J., & Greystoke, A. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.51 · Cited by 2
Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction
Bruno, R., Giordano, M., Giannini, R., Alì, G., Puppo, G., Ribechini, A., Chella, A., & Fontanini, G. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5479 · Cited by 2
Validation of EGFR mutation testing on cytological smears of lung cancer using the Idylla platform
Snell, C. E., McManus, S., Robinson, K., Lewis, W., Arandelovic, S., Lourie, R., & Harraway, J. R. (2022) · Pathology · doi:10.1016/j.pathol.2021.10.006 · Cited by 2
Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
de Moraes, F. C. A., Rodrigues, A. L. S. D. O., Pasqualotto, E., Cassemiro, J. F., Limachi-Choque, J., & Burbano, R. M. R. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03843-4 · Cited by 2
Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
Nicoś, M., Wojas‐Krawczyk, K., Krawczyk, P. A., Chmielewska, I., Wójcik-Superczyńska, M., Reszka, K., Kieszko, R., Góra-Florek, A., Dudek, M., Świniuch, D., et al. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.89217 · Cited by 2
The promise and pitfalls of the many methods of plasma genotyping
Komatsubara, K. M., Carvajal, R. D., & Sacher, A. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1229769 · Cited by 2
Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer
Son, C., Roh, M.-S., Yoon, N.-B., Lee, S., Kang, B., Um, S., & Lee, D. H. (2019) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_515_18 · Cited by 2
Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma.
Ma, M., Shi, C., Qian, J., & Han, B. (2017) · PubMed Central · Cited by 2
EGFR, EGFR TKI, and EMSI: a never-ending story.
Kim, Y. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.10 · Cited by 2
Profiling Circulating Tumour Cells for Clinical Applications
Goh, K. Y., & Lim, W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79228 · Cited by 2
Are Liquid Biopsies Ready for Prime Time of Clinical Applications?
Wang, S., & Wang, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.125 · Cited by 2
Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors
Moiseenko, F. V., Kuligina, E. S., Elsakova, E., & Имянитов, Е. Н. (2024) · Future Oncology · doi:10.1080/14796694.2024.2386925 · Cited by 1
Circulating tumor DNA: An alternative to tissue biopsy for detecting epidermal growth factor receptor mutation in non-small cell lung cancer
Soroar, M. K. I., Roy, S., Ara, H., Nur, S. A., Akanda, R. A., & Alam, M. M. (2026) · The International Journal of Biological Markers · doi:10.1177/03936155261445461 · Cited by 1
Altérations moléculaires anciennes et émergentes : quand les rechercher ?
Mignard, X., Ruppert, A.-M., Rabbe, N., Pontdeme, G., Antoine, M., Lacave, R., Lavolé, A., Cadranel, J. L., & Wislez, M. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30053-8 · Cited by 3
Circulating Tumor Cells and ctDNA in NSCLC
Fenizia, F., Rachiglio, A. M., Iannaccone, A., Chicchinelli, N., & Normanno, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00032-6 · Cited by 1
Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?
Oh, I. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.03 · Cited by 1
„Liquid biopsy“ – Einsatzmöglichkeiten in der molekularen Tumordiagnostik
Stögbauer, F., Weichert, W., & Pfarr, N. (2019) · Der Onkologe · doi:10.1007/s00761-019-00684-7 · Cited by 1
A Molecular Diagnosis of Cholangiocarcinoma suggested using Cell-free DNA following Multiple Unsuccessful Attempts at Obtaining a Tissue Diagnosis.
(2018) · doi:10.29199/caon.101014 · Cited by 1
Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Non–Small-Cell Lung Cancer
Sacher, A. G. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00125 · Cited by 1
[Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients].
Li, H., Yan, S., Liu, X., Liu, Y., Ma, L., Wang, Y., Liu, Y., & Cheng, Y. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.03 · Cited by 1
Core needle biopsy wash as a tool for acquiring additional diagnostic material for laboratory testing
Mojica, W. D., Cwiklinski, K., Jin, X., Liu, W., & Yergeau, D. A. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207318 · Cited by 1
EGFR-Directed Therapy in Lung Cancer
Kim, S. Y., Costa, D. B., Shibahara, D., Kobayashi, S. S., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009342285
Multi-Center Study of Resectable Lung Lesions by Ultra-Deep Sequencing of Targeted Genes in Plasma Cell-Free DNA to Assess Nodule Malignancy and Detect Lung CancersPreprint
Peng, M., Xie, Y., Li, X., Qian, Y., Tu, X., Yao, X., Cheng, F., Xu, F., Kong, D., He, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/453803 · Cited by 1
Expanding the gamut of circulating tumor DNA applications
Kaumaya, M., & Halmos, B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.87
Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications.
Herreros‐Pomares, A. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/137036 · Cited by 1

Authors: Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., Cole, R., McWalter, G., Walker, J., Dearden, S., Webster, A., Milenkova, T., & McCormack, R.
Affiliations: Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Hospital Regional Universitario de Málaga (ES)
AstraZeneca (United Kingdom) (GB)
Corresponding author: Douillard, Jean-Yves
ORCID: Douillard, Jean-Yves
Ostoros, Gyula
Cobo, Manuel
Ciuleanu, Tudor
Cole, Rebecca
Walker, Jill
Dearden, Simon
Milenkova, Tsveta
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2014-09
Volume: 9
Issue: 9
Pages: 1345-1353
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0000000000000263
PMC: PMC4224589
OpenAlex: W1978285367
Cited by: 448
References: 28
Citations by year: 2026: 2 · 2025: 7 · 2024: 8 · 2023: 16 · 2022: 20 · 2021: 37 · 2020: 44 · 2019: 69 · 2018: 70 · 2017: 72 · 2016: 63 · 2015: 38 · 2014: 2
FWCI: 46.71
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 438 d)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, EGFR mutation, non-small cell lung cancer, circulating tumor DNA, liquid biopsy, plasma DNA, tumor mutation status, treatment response, sensitivity and specificity, first-line therapy, Caucasian patients, EGFR tyrosine kinase inhibitors, objective response rate, progression-free survival, overall survival
MeSH terms: Gefitinib, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, DNA, Neoplasm, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinazolines, Single-Blind Method, Treatment Outcome, Disease-Free Survival, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks